Cancer Treatment Adaptations in the COVID-19 Era.
作者信息
Waisberg Federico, Enrico Diego, Angel Martín, Chacón Matías
机构信息
Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
出版信息
JCO Oncol Pract. 2020 Jun;16(6):305-307. doi: 10.1200/OP.20.00218. Epub 2020 Apr 23.
Abstract
摘要
相似文献
1
Cancer Treatment Adaptations in the COVID-19 Era.COVID-19 时代的癌症治疗调整
JCO Oncol Pract. 2020 Jun;16(6):305-307. doi: 10.1200/OP.20.00218. Epub 2020 Apr 23.
2
Palliative Care for Patients With Cancer in the COVID-19 Era.新冠疫情时代癌症患者的姑息治疗
JAMA Oncol. 2020 Oct 1;6(10):1527-1528. doi: 10.1001/jamaoncol.2020.1938.
3
Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.COVID-19大流行期间的肿瘤护理服务：研究创新与结果的契机。
JCO Oncol Pract. 2020 Aug;16(8):431-434. doi: 10.1200/OP.20.00326. Epub 2020 May 28.
4
Telehealth in Oncology During the COVID-19 Outbreak: Bringing the House Call Back Virtually.COVID-19疫情期间肿瘤学中的远程医疗：虚拟地重拾上门问诊服务
JCO Oncol Pract. 2020 Jun;16(6):289-293. doi: 10.1200/OP.20.00199. Epub 2020 May 4.
5
Disparities in Cancer Outcomes Due to COVID-19-A Tale of 2 Cities.COVID-19导致的癌症治疗结果差异——两个城市的故事
JAMA Oncol. 2020 Oct 1;6(10):1531-1532. doi: 10.1001/jamaoncol.2020.3327.
6
COVID-19 in Children With Cancer in New York City.纽约市癌症儿童中的 COVID-19 。
JAMA Oncol. 2020 Sep 1;6(9):1459-1460. doi: 10.1001/jamaoncol.2020.2028.
7
Rethinking Clinical Trials Reform During the COVID-19 Pandemic.新冠疫情期间对临床试验改革的反思
JAMA Oncol. 2020 Sep 1;6(9):1327-1329. doi: 10.1001/jamaoncol.2020.3142.
8
Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With Cancer.癌症患者合并SARS-CoV-2感染的发热性中性粒细胞减少症的管理
JCO Oncol Pract. 2020 Jun;16(6):348-349. doi: 10.1200/OP.20.00197. Epub 2020 May 5.
9
Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China.在中国新冠疫情传播期间照顾癌症患者的积极有效措施
JAMA Oncol. 2020 May 1;6(5):631-632. doi: 10.1001/jamaoncol.2020.1198.
10
Prevalence of Surface Contamination With SARS-CoV-2 in a Radiation Oncology Clinic.放射肿瘤学诊所中 SARS-CoV-2 表面污染的流行情况。
JAMA Oncol. 2020 Oct 1;6(10):1632-1634. doi: 10.1001/jamaoncol.2020.3552.
引用本文的文献
1
Recovery From COVID-19-Related Disruptions in Cancer Detection.从与新冠病毒相关的癌症检测中断中恢复。
JAMA Netw Open. 2024 Oct 1;7(10):e2439263. doi: 10.1001/jamanetworkopen.2024.39263.
2
Association between the COVID-19 pandemic and first cancer treatment modality: a population-based cohort study.COVID-19 大流行与癌症初始治疗方式的相关性：基于人群的队列研究。
CMAJ Open. 2023 May 9;11(3):E426-E433. doi: 10.9778/cmajo.20220102. Print 2023 May-Jun.
3
Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!COVID-19大流行期间口腔癌早期检测的远程筛查：诊断陷阱与潜在误解！
Oral Oncol. 2022 May;128:105845. doi: 10.1016/j.oraloncology.2022.105845. Epub 2022 Mar 28.
4
Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic.电子患者症状管理程序，以支持在 COVID-19 大流行期间在家中接受癌症治疗的患者。
Value Health. 2022 Jun;25(6):931-936. doi: 10.1016/j.jval.2022.01.023. Epub 2022 Mar 23.
5
First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.一线顺铂、多西他赛和西妥昔单抗用于复发或转移性头颈癌患者：一项多中心队列研究。
World J Clin Oncol. 2022 Feb 24;13(2):147-158. doi: 10.5306/wjco.v13.i2.147.
6
Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study.秘鲁首次全国性紧急新冠疫情期间的肿瘤护理：一项多中心描述性研究。
Cancer Manag Res. 2022 Mar 8;14:1075-1085. doi: 10.2147/CMAR.S350038. eCollection 2022.
7
Telescreening as an alternate modality for early detection of oral cancer.远程筛查作为口腔癌早期检测的替代方式。
Oral Oncol. 2022 Apr;127:105785. doi: 10.1016/j.oraloncology.2022.105785. Epub 2022 Feb 21.
8
[Not Available].[无可用内容]。
Rev Malad Respir Actual. 2021 Sep;13(2):2S280-2S291. doi: 10.1016/S1877-1203(21)00121-X. Epub 2021 Oct 11.
9
Meeting the Challenges in Cancer Care Management During the SARS-Cov-2 Pandemic: A Retrospective Analysis.应对 SARS-CoV-2 大流行期间癌症护理管理中的挑战：回顾性分析。
Cancer Control. 2021 Jan-Dec;28:10732748211045275. doi: 10.1177/10732748211045275.
10
Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.COVID-19 大流行对癌症患者管理的影响：巴黎一所大学医院癌症门诊的经验。
Clin Med (Lond). 2021 Sep;21(5):e552-e555. doi: 10.7861/clinmed.2020-0666. Epub 2021 Aug 2.
本文引用的文献
1
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
2
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.接受 PD-1 阻断治疗的黑色素瘤患者的长期结果和再治疗应答。
J Clin Oncol. 2020 May 20;38(15):1655-1663. doi: 10.1200/JCO.19.01464. Epub 2020 Feb 13.
3
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.在一线上皮性卵巢癌、输卵管癌或原发性腹膜癌治疗中进行每周剂量密集化疗（ICON8）：GCIG 三期随机对照试验的主要无进展生存分析结果。
Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29.
4
Treatment duration of checkpoint inhibitors for NSCLC.非小细胞肺癌检查点抑制剂的治疗持续时间。
Lancet Respir Med. 2019 Oct;7(10):835-837. doi: 10.1016/S2213-2600(19)30192-4. Epub 2019 Aug 7.
5
Adjuvant therapy in renal cell carcinoma.肾细胞癌的辅助治疗。
Cancer. 2019 Sep 1;125(17):2935-2944. doi: 10.1002/cncr.32144. Epub 2019 Jun 21.
6
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.曲妥珠单抗辅助治疗 HER2 阳性早期乳腺癌 6 个月与 12 个月的疗效对比（PERSEPHONE）：一项随机、III 期非劣效性试验的 4 年无病生存结果。
Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6.
7
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.9 周与 1 年曲妥珠单抗辅助化疗联合治疗：III 期随机短程 HER 研究的最终结果‡。
Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.
8
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.III期结肠癌辅助化疗的疗程
N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.
9
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.XELOX方案与FOLFOX方案治疗转移性结直肠癌的比较：一项更新的荟萃分析。
Cancer Invest. 2016;34(2):94-104. doi: 10.3109/07357907.2015.1104689. Epub 2016 Feb 11.
10
Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer.辅助化疗的时机与 III 期结肠癌患者生存的关系。
Eur J Cancer. 2015 Nov;51(17):2553-61. doi: 10.1016/j.ejca.2015.08.016. Epub 2015 Sep 7.
Zotero 插件